An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission. Results from the multicenter Phase II study, ARTEMIS-UC, were published in The New England Journal of Medicine . Ulcerative colitis is a type of inflammatory bowel disease (IBD) that damages the digestive tract, causing stomach cramping, diarrhea, weight loss and rectal bleeding.
It affects as many as 900,000 people in the U.S., and current treatments are often only minimally effective.
Findings from this study are poised to have a remarkable impact on treatment for ulcerative colitis and IBD overall. The investigational therapy was generated based on the concept of precision medicine; it shows promise as being both anti-inflammatory and anti-fibrotic; it represents a potential turning point in drug development and discovery; and it could change how this complex disease is treated in the future." Stephan Targan, MD, study senior author and IBD research pioneer, the Feintech Family Chair in Inflammatory Bowel Disease and executive director of the F.
Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai The study evaluated a therapy developed by Cedars-Sinai clinician-scientists called tulisokibart (previously PRA023)-;a man-made monoclonal antibody that acts like endogenous antibodies. It is designed to target and b.
